Anokion SA

Promoting IMMUNE TOLERANCE, ameliorating disease

Many therapeutic protein drugs are perceived by the body as foreign entities and are hence targeted for attack and clearance by the immune system, thus rendering treatment ineffective and potentially dangerous. Anokions platform immune tolerance technology harnesses the power of natural immune regulation by engineering therapeutic proteins to be perceived as self entities, thereby offering a means to reduce immunogenicity of existing therapeutics and further enable clinical translation of proteins previously thought to be too immunogenic for repeated use.

Patients suffering from autoimmune diseases harbor immune cells that erroneously recognize naturally occurring self-proteins as foreign, causing tissue destruction and inflammation. The current therapeutic modality for treating such

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No milestones

No Jobs

No videos and documents

TOP 100 Swiss Startup Award

The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.

Website

EPFL Spin-Off

Website

Anokion SA

Promoting IMMUNE TOLERANCE, ameliorating disease

Headquarter:
Ecublens

Foundation Date:
March 2010

Technology:

  • Biotech

Support received

  • Support TOP 100